Please assess the completion status of the following clinical trial:

Trial Title: Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 12-70 years of age (inclusive).~2. Diagnosis of asthma for at least 6 months.~3. Morning FEV1 of 40-80% normal.~4. Demonstrated reversible airflow restriction.~5. Non-smokers.~6. On moderate doses of ICS with inadequate asthma control.~7. Signed ICF~Exclusion Criteria:~1. Diagnosis of COPD.~2. Uncontrolled systemic illness.~3. Hypersensitivity to any component of ZYFLO CR~4. Any patient with an unscheduled visit to an ER or hospital for asthma exacerbation within past 3 months.~5. History of hepatitis or active liver disease.~6. ALT greater than 3xULN.~7. History of HIV infection~8. Recent history of drug or alcohol abuse.~9. Oral corticosteroids within one month, cromolyn sodium or nedocromil within 14 days, theophylline, LABA, ZYFLO, or leukotriene modifiers, warfarin or propranolol, inhaled anti-cholinergics, or combination LABA/ICS.~10. Omalizumab within 3 months.~11. Pregnant female.~12. Participation with 30 days in investigational study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Zileuton CR
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).